cetirizine and Hay Fever studies

Cetirizine: A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.
cetirizine : A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively.

Research Excerpts

Excerpt	Relevance	Reference
"The CIRANO study suggests that levocetirizine is effective on PER symptoms, including a transient improvement in loss of smell, and that this improvement concurs more with reduction of nasal inflammation than of nasal patency."	9.16	The loss of smell in persistent allergic rhinitis is improved by levocetirizine due to reduction of nasal inflammation but not nasal congestion (the CIRANO study). ( Alobid, I; Bernal-Sprekelsen, M; Centellas, S; García-Piñero, A; Guilemany, JM; Mariño, FS; Mullol, J; Picado, C; Valero, A, 2012)
"To evaluate the effects of cetirizine hydrochloride (5 mg)-pseudoephedrine hydrochloride (120 mg) (cetirizine-D) twice daily on AR and asthma symptoms, pulmonary function, and asthma-related quality of life in 274 patients with confirmed seasonal AR and concomitant mild-to-moderate asthma."	9.12	Comparison of cetirizine-pseudoephedrine and placebo in patients with seasonal allergic rhinitis and concomitant mild-to-moderate asthma: randomized, double-blind study. ( Chapman, D; de Guia, EC; Finn, AF; Hewlett, D; Kramer, B; LaForce, C; Nathan, RA; Ratner, P, 2006)
"Cetirizine, a highly specific H1 receptor antagonist with modest sedation and anticholinergic effects at the higher doses required for bronchodilation, may be useful for treating concomitant allergy and symptoms of asthma."	9.08	Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma. ( Aaronson, DW, 1996)
"This study explored the safety and efficacy of cetirizine for treatment of allergic rhinitis and asthma."	9.08	Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. ( Findlay, SR; Glovsky, MM; Grant, JA; Grossman, J; Kaiser, H; Meltzer, EO; Mitchell, DQ; Nicodemus, CF; Pearlman, D; Selner, J, 1995)
"Clinical trials of a new histamine H1-blocker of the III generation zyrtec (cetirizine) manufactured in Belgium (UCB) demonstrated its high efficacy in pollenosis and chronic idiopathic urticaria."	9.07	[The efficacy of the Zirtek (cetirizine) preparation in chronic recurrent urticaria and seasonal allergic rhinitis]. ( Androsov, VN; Belostotskaia, OI; Il'ina, NI, 1994)
"Levocetirizine (LCZ) is a second-generation antihistamine that was approved in January 2008 for the relief of symptoms of seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR), and chronic idiopathic urticaria (CIU) in adults and children aged > or = 6 years."	8.85	Levocetirizine for the treatment of allergic rhinitis and chronic idiopathic urticaria in adults and children. ( Borja-Hart, N; Ghin, HL; Perez, A; Robles, GI; Singh-Franco, D, 2009)
"Levocetirizine (Xyzal) is a selective, potent, oral histamine H(1) receptor antagonist of the latest generation that is licensed for the symptomatic treatment of allergic rhinitis (including persistent allergic rhinitis [PER]) and chronic idiopathic urticaria (CIU)."	8.83	Levocetirizine: a review of its use in the management of allergic rhinitis and skin allergies. ( Hair, PI; Scott, LJ, 2006)
"Levocetirizine has been shown in observational studies in the west as an effective and satisfactory therapy for patients with allergic respiratory and skin disease."	6.75	An open-label, multicentre study of levocetirizine for the treatment of allergic rhinitis and urticaria in Taiwanese patients. ( Fang, SY; Huangs, CY; Lee, JY; Lin, DY; Perng, DW, 2010)
"Levocetirizine treatment induced significant symptom relief (P=0."	6.71	Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. ( Ciprandi, G; Cirillo, I; Tosca, MA; Vizzaccaro, A, 2004)
" It is hypothesized that the platelet activating factor receptor antagonist ginkgolide B (GB) and the carotenoid antioxidant astaxanthin (ASX) interact with antihistamines cetirizine dihydrochloride (CTZ) and azelastine (AZE) to potentiate their ability to downregulate potentially pathological immune activation."	5.38	In vitro suppression of lymphocyte activation in patients with seasonal allergic rhinitis and pollen-related asthma by cetirizine or azelastine in combination with ginkgolide B or astaxanthin. ( Abal, A; Al-Awadhi, R; Al-Sharah, S; Arifhodzic, N; Azeamouzi, C; Haines, D; Mahmoud, FF; Tosaki, A, 2012)
"The CIRANO study suggests that levocetirizine is effective on PER symptoms, including a transient improvement in loss of smell, and that this improvement concurs more with reduction of nasal inflammation than of nasal patency."	5.16	The loss of smell in persistent allergic rhinitis is improved by levocetirizine due to reduction of nasal inflammation but not nasal congestion (the CIRANO study). ( Alobid, I; Bernal-Sprekelsen, M; Centellas, S; García-Piñero, A; Guilemany, JM; Mariño, FS; Mullol, J; Picado, C; Valero, A, 2012)
"We sought to investigate the efficacy of the DP1 antagonist laropiprant (alone or with montelukast) in asthma and seasonal AR and explore whether sequence variations in PTGDR are associated with asthma severity."	5.14	Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis. ( Dass, SB; Lai, E; Liu, N; Loeys, T; Philip, G; Reiss, TF; van Adelsberg, J; Wong, P, 2009)
"To evaluate the effects of cetirizine hydrochloride (5 mg)-pseudoephedrine hydrochloride (120 mg) (cetirizine-D) twice daily on AR and asthma symptoms, pulmonary function, and asthma-related quality of life in 274 patients with confirmed seasonal AR and concomitant mild-to-moderate asthma."	5.12	Comparison of cetirizine-pseudoephedrine and placebo in patients with seasonal allergic rhinitis and concomitant mild-to-moderate asthma: randomized, double-blind study. ( Chapman, D; de Guia, EC; Finn, AF; Hewlett, D; Kramer, B; LaForce, C; Nathan, RA; Ratner, P, 2006)
"To compare the efficacy and tolerability of butterbur (Petasites hybridus) with cetirizine in patients with seasonal allergic rhinitis (hay fever)."	5.10	Randomised controlled trial of butterbur and cetirizine for treating seasonal allergic rhinitis. ( Schapowal, A, 2002)
"Twenty-one patients with seasonal allergic rhinitis and asthma were enrolled into a single-blind, placebo-controlled, crossover study comparing 2 weeks of 1) 400 microg inhaled plus 200 microg intranasal budesonide once daily and 2) 10 mg montelukast plus 10 mg cetirizine once daily."	5.09	Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis. ( Coutie, WJ; Gardiner, Q; Lipworth, BJ; Orr, LC; Sims, EJ; White, PS; Wilson, AM, 2001)
"To compare the antiasthmatic efficacy of inflammatory mediator blockade versus topical corticosteroid therapy in patients with seasonal allergic rhinitis (SAR) and asthma, 14 patients were enrolled into a single-blind, double-dummy, placebo-controlled crossover study comparing 2 wk therapy of (1) 400 microgram orally inhaled budesonide plus 200 microgram intranasal budesonide (BUD) or (2) 10 mg oral montelukast plus 10 mg oral cetirizine (ML + CZ)."	5.09	Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma. ( Dempsey, OJ; Lipworth, BJ; Orr, LC; Sims, EJ; Wilson, AM, 2000)
" However from 22 to 24 h after the first dose cetirizine was significantly superior to fexofenadine for the major symptom complex score and for sneezing."	5.09	Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. ( Burtin, B; De Vos, C; Donnelly, F; Horak, F; Kavina, A; Stübner, P; Zieglmayer, R, 2001)
"Cetirizine, a highly specific H1 receptor antagonist with modest sedation and anticholinergic effects at the higher doses required for bronchodilation, may be useful for treating concomitant allergy and symptoms of asthma."	5.08	Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma. ( Aaronson, DW, 1996)
"This study explored the safety and efficacy of cetirizine for treatment of allergic rhinitis and asthma."	5.08	Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. ( Findlay, SR; Glovsky, MM; Grant, JA; Grossman, J; Kaiser, H; Meltzer, EO; Mitchell, DQ; Nicodemus, CF; Pearlman, D; Selner, J, 1995)
"Clinical trials of a new histamine H1-blocker of the III generation zyrtec (cetirizine) manufactured in Belgium (UCB) demonstrated its high efficacy in pollenosis and chronic idiopathic urticaria."	5.07	[The efficacy of the Zirtek (cetirizine) preparation in chronic recurrent urticaria and seasonal allergic rhinitis]. ( Androsov, VN; Belostotskaia, OI; Il'ina, NI, 1994)
"Levocetirizine (LCZ) is a second-generation antihistamine that was approved in January 2008 for the relief of symptoms of seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR), and chronic idiopathic urticaria (CIU) in adults and children aged > or = 6 years."	4.85	Levocetirizine for the treatment of allergic rhinitis and chronic idiopathic urticaria in adults and children. ( Borja-Hart, N; Ghin, HL; Perez, A; Robles, GI; Singh-Franco, D, 2009)
"Levocetirizine (Xyzal) is a selective, potent, oral histamine H(1) receptor antagonist of the latest generation that is licensed for the symptomatic treatment of allergic rhinitis (including persistent allergic rhinitis [PER]) and chronic idiopathic urticaria (CIU)."	4.83	Levocetirizine: a review of its use in the management of allergic rhinitis and skin allergies. ( Hair, PI; Scott, LJ, 2006)
"Levocetirizine and desloratadine are newer antihistamines indicated for the treatment of allergic rhinitis and chronic idiopathic urticaria."	4.82	A review of the evidence from comparative studies of levocetirizine and desloratadine for the symptoms of allergic rhinitis. ( Canonica, GW; Passalacqua, G, 2005)
"The presented results indicate the effectiveness of theoritin and cetirizine in the treatment of patients with seasonal exacerbation of allergic rhinitis, comorbid for acute respiratory viral infections."	4.12	[Modern H1 antihistamines in the treatment of patients with allergic rhinitis and comorbid acute respiratory infections]. ( Miroshnichenko, NA; Nikolaeva, YO; Ovchinnikov, AY, 2022)
"Cetirizine 10 mg was statistically significantly more efficacious than placebo in the treatment of SAR symptoms in children ages 6-11 years."	2.84	Randomized, placebo-controlled study of cetirizine and loratadine in children with seasonal allergic rhinitis. ( Berger, WE; Franklin, KB; LaForce, CF; Nayak, AS; Patel, MK; Urdaneta, ER; Wu, MM, 2017)
"Acupuncture is frequently used to treat seasonal allergic rhinitis (SAR) despite limited scientific evidence."	2.78	Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. ( Brinkhaus, B; Hummelsberger, J; Linde, K; Niggemann, B; Ortiz, M; Pfab, F; Ring, J; Roll, S; Treszl, A; Wegscheider, K; Willich, SN; Witt, CM; Zuberbier, T, 2013)
"Levocetirizine was well tolerated and was significantly more effective than placebo in improving the naso-ocular symptoms and health-related quality of life in US patients with SAR."	2.75	Efficacy and safety of levocetirizine in improving symptoms and health-related quality of life in US adults with seasonal allergic rhinitis: a randomized, placebo-controlled study. ( Gawchik, S; Georges, G; Haeusler, JM; Segall, N, 2010)
"Cetirizine was similar."	2.75	The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. ( Horak, F; Lemell, P; Zieglmayer, P; Zieglmayer, R, 2010)
"Rupatadine is a better choice for seasonal allergic rhinitis compared with levocetirizine because of its better efficacy and safety profile."	2.75	Rupatadine and levocetirizine for seasonal allergic rhinitis: a comparative study of efficacy and safety. ( Allala, U; Jaida, J; Maiti, R; Palani, A; Rahman, J, 2010)
"Levocetirizine has been shown in observational studies in the west as an effective and satisfactory therapy for patients with allergic respiratory and skin disease."	2.75	An open-label, multicentre study of levocetirizine for the treatment of allergic rhinitis and urticaria in Taiwanese patients. ( Fang, SY; Huangs, CY; Lee, JY; Lin, DY; Perng, DW, 2010)
"Bilastine is a new non-sedative H(1) receptor antagonist, indicated for the treatment of allergic rhinitis (AR) (seasonal and perennial)."	2.74	Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. ( Agache, I; Bachert, C; Fouquert, L; Kuna, P; Nowacki, Z; Roger, A; Sologuren, A; Valiente, R; van Cauwenberge, P, 2009)
"Levocetirizine treatment also correlated with a significant increase in the percentage of CD4+CD25+ T cells (P<0."	2.73	Levocetirizine modulates lymphocyte activation in patients with allergic rhinitis. ( Arifhodzic, N; Haines, D; Mahmoud, F; Novotney, L, 2008)
" Studies comparing these routes of administration of an antihistamine regarding efficacy and pharmacokinetic profile are lacking."	2.73	Clinical efficacy and pharmacokinetic profiles of intranasal and oral cetirizine in a repeated allergen challenge model of allergic rhinitis. ( Aldén-Raboisson, M; Andersson, M; Borgå, O; Greiff, L; Korsgren, M; Larsson, L; Malmqvist, U, 2007)
"Levocetirizine was well tolerated."	2.72	Levocetirizine as treatment for symptoms of seasonal allergic rhinitis. ( Bertrand, B; Jorissen, M; Stiels, B; Vandenbulcke, K, 2006)
"Levocetirizine was shown to improve quality of life and symptoms and to decrease the overall costs of the disease over the 6-month treatment period."	2.71	Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. ( Bachert, C; Bousquet, J; Canonica, GW; Durham, SR; Klimek, L; Mullol, J; Van Cauwenberge, PB; Van Hammée, G, 2004)
"Levocetirizine is a potent and highly selective H1-antihistamine with a proven efficacy in adults."	2.71	Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. ( Alt, R; Billard, E; de Blic, J; Pujazon, MC; Wahn, U, 2005)
"Japanese cedar pollinosis, a common disease with morbidity of approximately 20% in the Japanese population, is characterized by subjectively irritating symptoms during an annual 3-month period."	2.71	The efficacy of short-term administration of 3 antihistamines vs placebo under natural exposure to Japanese cedar pollen. ( Fujieda, S; Hyo, S; Kawada, R; Kitazawa, S; Takenaka, H, 2005)
"The objective of the present study was to compare the efficacy and tolerability of azelastine nasal spray administered at the recommended dosage of 2 sprays per nostril twice daily with those of cetirizine in the treatment of moderate to severe SAR."	2.71	Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis. ( Berger, W; Bernstein, J; Corren, J; Nayak, A; Sacks, H; Storms, W, 2005)
"Cetirizine treatment induced a significant decrease of IL4 (p<0."	2.71	Cetirizine reduces cytokines and inflammatory cells in children with perennial allergic rhinitis. ( Ciprandi, G; Milanese, M; Ricca, V; Tosca, MA, 2004)
" Safety was assessed on routine laboratory assays and recording vital signs and adverse events (AEs)."	2.71	Clinical study of the therapeutic efficacy and safety of emedastine difumarate versus cetirizine in the treatment of seasonal allergic rhinitis. ( Assandri, A; Corrado, ME; Horak, F; Kavina, A; Mion, A; Stübner, P; Zieglmayer, R, 2004)
"Cetirizine-treated patients reported significantly greater improvement in overall HRQL (P < 0."	2.71	The health-related quality of life effects of once-daily cetirizine HCl in patients with seasonal allergic rhinitis: a randomized double-blind, placebo-controlled trial. ( Champan, D; Greos, L; Kramer, B; Leidy, NK; Nayak, A; Noonan, MJ; Olufade, AO; Raphael, GD, 2003)
"Levocetirizine treatment induced significant symptom relief (P=0."	2.71	Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. ( Ciprandi, G; Cirillo, I; Tosca, MA; Vizzaccaro, A, 2004)
"Cetirizine was more effective in relieving nasal discharge and sneezing compared to nimesulide."	2.70	Efficacy of nimesulide alone and in combination with cetirizine in acute allergic rhinitis. ( Gupta, U; Kotwani, A; Puri, R, 2001)
"Levocetirizine was significantly superior to placebo in reducing symptom severity with an important global treatment effect (P = 0."	2.70	Efficacy and safety of levocetirizine in seasonal allergic rhinitis. ( Arendt, C; Leynadier, F; Mees, K; Pinelli, ME, 2001)
"Cetirizine is a newer once-daily selective H1-antagonist."	2.69	Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. ( Briscoe, M; Day, JH; Widlitz, MD, 1998)
" Twenty-four hours after intake, the dose-response curve of nasal obstruction to histamine was significantly lower after treatment with cetirizine compared with placebo (P < 0."	2.69	Nasal effect of cetirizine and loratadine at 24 hours in patients with allergic rhinitis. ( Benabdesselam, O; Frossard, N; Glasser, N; Lacronique, J; Melac, M; Pauli, G, 1998)
"Cetirizine was more effective on histamine skin test responses."	2.69	Comparison between nasal provocation tests and skin tests in patients treated with loratadine and cetirizine. ( Bousquet, J; Demoly, P; Harris, AG; Michel, FB; Persi, L; Tisserand, B, 1999)
"Mizolastine is a potent and selective H1-receptor antagonist with additional anti-allergic properties."	2.69	Comparison of the efficacy, safety, and onset of action of mizolastine, cetirizine, and placebo in the management of seasonal allergic rhinoconjunctivitis. MIZOCET Study Group. ( Attali, P; Ben-Soussen, P; Daele, J; Sabbah, A; Wade, AG, 1999)
" In addition, assessment was made immediately before dosing in the morning for the previous 30 minutes."	2.69	Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. ( Bousquet, J; Howarth, PH; Reynolds, R; Roi, L; Stern, MA, 1999)
" Somnolence scores were similar for both groups at baseline and at the time of dosing (8:00 AM)."	2.69	Loratadine versus cetirizine: assessment of somnolence and motivation during the workday. ( Gates, D; Greiding, L; Heithoff, K; Ramon, F; Salmun, LM; Scharf, M, 2000)
" Major and total symptom complex scores, global efficacy and overall satisfaction, and adverse events were assessed."	2.68	Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. ( Meltzer, EO; Weiler, JM; Widlitz, MD, 1996)
"Cetirizine is an antihistamine used in the treatment of allergic rhinoconjunctivitis, that has antiallergic activity."	2.68	Continuous versus on demand treatment with cetirizine for allergic rhinitis. ( Canonica, GW; Ciprandi, G; Mincarini, M; Passalacqua, G; Ricca, V, 1997)
" Both drugs were well tolerated and their adverse event profiles were similar."	2.68	Comparison of efficacy, safety, and skin test inhibition of cetirizine and astemizole. ( Berkowitz, RB; Dockhorn, R; Findlay, S; Howland, WC; Lockey, R; Mitchell, DQ; Woehler, T, 1996)
"Ebastine is a new histamine H1-receptor blocker that may differ in efficacy from currently used second-generation agents."	2.68	Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults. ( Bremard-Oury, C; Gehanno, P; Zeisser, P, 1996)
"1% increased dosage to 10 mg/d, and 41."	2.68	Dose-ranging comparative evaluation of cetirizine in patients with seasonal allergic rhinitis. ( DuBuske, L, 1995)
" In conclusion, this study found cetirizine and loratadine to have similar nasal efficacy at therapeutic dosage 4 h after intake, whereas cetirizine was more effective than loratadine 1."	2.68	Onset of action in the nasal antihistaminic effect of cetirizine and loratadine in patients with allergic rhinitis. ( Benabdesselam, O; Braun, JJ; Frossard, N; Glasser, N; Lacronique, J; Melac, M; Pauli, G, 1997)
" Both were dosed at 10 mg/day."	2.68	Loratadine treatment of rhinitis due to pollen allergy reduces epithelial ICAM-1 expression. ( Canonica, GW; Ciprandi, G; Danzig, M; Passalacqua, G; Pronzato, C; Ricca, V, 1997)
"Cetirizine is an antihistamine, largely used in the treatment of allergic rhinoconjunctivitis, which also exerts anti-allergic activity."	2.68	Cetirizine treatment of rhinitis in children with pollen allergy: evidence of its antiallergic activity. ( Bagnasco, M; Canonica, GW; Ciprandi, G; Passalacqua, G; Ricca, V; Riccio, AM; Tosca, M, 1997)
"Cetirizine is a new antihistamine with greater selectivity for the histamine H1 receptor and a low rate of hepatic metabolism."	2.68	Comparative study of cetirizine and terfenadine versus placebo in the symptomatic management of seasonal allergic rhinitis. ( Dockhorn, R; Grossman, J; Lockey, RF; Lumry, W; Mitchell, DQ; Widlitz, MD; Woehler, T, 1996)
"Cetirizine was more active than placebo for each symptom evaluated both by parents and investigators."	2.67	Cetirizine for seasonal allergic rhinitis in children aged 2-6 years. A double-blind comparison with placebo. ( Allegra, L; Baelde, Y; Paupe, J; Wieseman, HG, 1993)
" Compliance was checked and found to be less than 80% of the prescribed dosage in 2 cetirizine patients."	2.67	A placebo-controlled trial of cetirizine in seasonal allergic rhino-conjunctivitis in children aged 6 to 12 years. ( Candiani, R; Masi, M; van de Venne, H, 1993)
"Cetirizine was significantly more effective than placebo in reducing the clinical symptoms of rhinitis near in 60% patients."	2.67	[Cetirizine for treating allergic seasonal rhinitis]. ( Grzelewska-Rzymowska, I; Kalinowska-Graczyk, M; Kopczyński, J; Rozniecki, J, 1992)
"Cetirizine was well tolerated, with sedation being the most common adverse experience, increasing in frequency at higher doses."	2.67	Double-blind comparison of cetirizine and placebo in the treatment of seasonal rhinitis. ( Altman, R; Brandon, ML; Buchman, E; Connell, JT; Dockhorn, R; Falliers, CJ; Leese, PT; Miller, J; Wasserman, SI; Zeterberg, JM, 1991)
"Cetirizine is a new selective H1-antagonist."	2.67	Effect of cetirizine in a conjunctival provocation test with allergens. ( Pécoud, AR; Schoeneich, M, 1990)
"Cetirizine was rapidly absorbed with mean peak cetirizine concentrations of 427."	2.66	Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. ( Chen, XY; Simons, FE; Simons, KJ; Watson, WT, 1989)
" Three-day repeat dosing of the intranasal solution GSK1004723 1,000 μg also demonstrated a statistically significant attenuation of nasal symptoms, but was less than seen with cetirizine and GSK835726 and caused initial nasal discomfort."	2.48	The efficacy and tolerability of two novel H(1)/H(3) receptor antagonists in seasonal allergic rhinitis. ( Ambery, C; Daley-Yates, P; McQuade, B; Oliver, A; Sweeney, L; Watson, J, 2012)
"Levocetirizine has several pharmacokinetic properties that are desirable for an antihistamine providing a combination of both potency and safety."	2.47	Pharmacokinetic evaluation of levocetirizine. ( Ferrer, M, 2011)
"Levocetirizine was consistently superior to placebo regardless of baseline symptom score levels."	2.47	Improving SAR symptoms with levocetirizine: evaluating active and placebo effects in pollen challenge vs. natural exposure studies. ( Bedenbaugh, A; Boev, R; Haeusler, JM; Song, D, 2011)
"Fexofenadine was associated with significantly lower nasal congestion scores compared with placebo in 4 studies (P <- 0."	2.45	A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis. ( Bachert, C, 2009)
" No major cytochrome P450 inhibition has been reported with desloratadine, fexofenadine and levocetirizine, and the bioavailability of desloratadine is minimally affected by drugs interfering with transporter molecules."	2.44	Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. ( Devillier, P; Faisy, C; Roche, N, 2008)
"Histamine is a key mediator of the allergic immediate reaction."	2.43	[Oral second generation antihistamines in allergic rhinitis]. ( Riechelmann, H, 2005)
"Levocetirizine has a favorable pharmacokinetic profile; it is rapidly and extensively absorbed, minimally metabolized, and has a lower volume of distribution (V(d)) than some other second-generation antihistamines."	2.42	Levocetirizine: a new selective H1 receptor antagonist for use in allergic disorders. ( Day, JH; Ellis, AK; Rafeiro, E, 2004)
"Cetirizine hydrochloride is an orally-active and selective histamine (H(1))-receptor antagonist."	2.42	Review of cetirizine hydrochloride for the treatment of allergic disorders. ( Dinakar, C; Portnoy, JM, 2004)
" black triangle The bioavailability of cetirizine and pseudoephedrine is similar after administration of cetirizine/pseudoephedrine 5/120 mg bilayer tablets or coadministration of cetirizine 5 mg tablets plus pseudoephedrine sustained-release (SR) 120 mg caplets."	2.41	Cetirizine/pseudoephedrine. ( Jarvis, B; Wellington, K, 2001)
" The recommended adult dosage of this agent is 5 or 10 mg/d."	2.38	Cetirizine: a new, nonsedating antihistamine. ( Barnes, CL; McKenzie, CA; Poinsett-Holmes, K; Webster, KD, 1993)
"In this review of the current treatment of seasonal allergic rhinitis, the clinical studies that compare these four new second-generation H1-receptor antagonists are discussed."	2.38	H1-receptor antagonist treatment of seasonal allergic rhinitis. ( Kaiser, HB, 1990)
"Cetirizine treatment also significantly reduced symptom severity in Italian children with SAR and was safe."	1.56	Cetirizine modifies quality of life and symptoms in children with seasonal allergic rhinitis: a pilot study. ( Benazzo, M; Ciprandi, G; Corsico, A; Leonardi, S; Licari, A; Marseglia, GL; Miraglia Del Giudice, M; Peroni, D; Salpietro, C, 2020)
" It is hypothesized that the platelet activating factor receptor antagonist ginkgolide B (GB) and the carotenoid antioxidant astaxanthin (ASX) interact with antihistamines cetirizine dihydrochloride (CTZ) and azelastine (AZE) to potentiate their ability to downregulate potentially pathological immune activation."	1.38	In vitro suppression of lymphocyte activation in patients with seasonal allergic rhinitis and pollen-related asthma by cetirizine or azelastine in combination with ginkgolide B or astaxanthin. ( Abal, A; Al-Awadhi, R; Al-Sharah, S; Arifhodzic, N; Azeamouzi, C; Haines, D; Mahmoud, FF; Tosaki, A, 2012)
" The first-generation H(1)-antihistamines are associated with marked adverse effects such as sedation, sleepiness/drowsiness as well as difficulties in learning and cognitive processing; thus, they are recommended for limited or discontinued use in children with AR or CIU."	1.37	Evidence for clinical safety, efficacy, and parent and physician perceptions of levocetirizine for the treatment of children with allergic disease. ( Kurzawa, R; Pampura, AN; Papadopoulos, NG; Spičák, V, 2011)
" Second-generation antihistamines have become increasingly popular because of their comparable efficacy and lower incidence of adverse effects relative to their first-generation counterparts, and the safety and efficacy of this drug class are established in the adult population."	1.35	Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast. ( Moeller, ML; Nahata, MC; Phan, H, 2009)
"Montelukast has not been reported to have major effects on sneezing and itching in the clinic but reduces nasal obstruction (lower nasal airway pressure or nasal patency)."	1.35	Differential responses to various classes of drugs in a model of allergic rhinitis in guinea pigs. ( Al Suleimani, YM; Dong, Y; Walker, MJ, 2008)
"The long QT syndrome is a rare disease."	1.33	Long QT syndrome in a patient with allergic rhinoconjunctivitis and auto-immune diabetes: focus on the choice of anti-H1 drugs. ( Codreanu, A; de Chillou, C; Moneret-Vautrin, DA, 2006)
"Allergic rhinitis, also known as hay fever, rose fever or summer catarrh, is a major challenge to health professionals."	1.32	Mast cell stabilization, lipoxygenase inhibition, hyaluronidase inhibition, antihistaminic and antispasmodic activities of Aller-7, a novel botanical formulation for allergic rhinitis. ( Amit, A; Bagchi, D; Bagchi, M; D'Souza, P; Pratibha, N; Saxena, VS; Stohs, SJ, 2003)
" Since V/F increased more rapidly with age than CL/F, a nonlinear increase in half-life was seen, from < 4 h in infants to near the adult value at 12 years of age."	1.32	Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 years. ( Aarons, L; de Longueville, M; Hussein, Z; Majid, O; Pitsiu, M; Stockis, A, 2004)
" To establish dose-response relationships for oral antihistamines in monkeys, we measured the suppression of wheal-and-flare reactions by two such agents, oral cetirizine (CET) 0."	1.27	A primate model for the evaluation of antihistamines. ( Doyle, W; Fireman, P; Skoner, D; Tanner, E, 1987)

Research

Studies (174)

Authors

Clinical Trials (23)

Trial Overview

Trial Outcomes

Change From Baseline in Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score

Timeframe	Studies, this research(%)	All Research%
pre-1990	6 (3.45)	18.7374
1990's	53 (30.46)	18.2507
2000's	82 (47.13)	29.6817
2010's	28 (16.09)	24.3611
2020's	5 (2.87)	2.80

Authors	Studies
Ovchinnikov, AY	1
Miroshnichenko, NA	1
Nikolaeva, YO	1
Arpornchayanon, W	1
Klinprung, S	1
Chansakaow, S	1
Hanprasertpong, N	1
Chaiyasate, S	1
Tokuda, M	1
Tamura, H	1
Yonekura, S	2
Okamoto, Y	2
Sakurai, D	2
Iinuma, T	2
Sakurai, T	2
Yoneda, R	1
Kurita, J	1
Hanazawa, T	2
Kawasaki, Y	1
Jordakieva, G	1
Kundi, M	1
Lemell, P	2
Zieglmayer, R	5
Zieglmayer, P	2
Jensen-Jarolim, E	1
Crevenna, R	1
Benazzo, M	1
Leonardi, S	1
Corsico, A	1
Licari, A	1
Miraglia Del Giudice, M	2
Peroni, D	1
Salpietro, C	1
Marseglia, GL	1
Ciprandi, G	10
Ellis, AK	3
DeVeaux, M	1
Steacy, L	1
Ramesh, D	1
Suprun, M	1
Langdon, S	1
Wang, CQ	1
Adams, D	1
Thiele, J	1
Walker, T	1
Perlee, LT	1
O'Brien, MP	1
Nayak, AS	1
Berger, WE	1
LaForce, CF	1
Urdaneta, ER	1
Patel, MK	1
Franklin, KB	1
Wu, MM	1
Otsuka, H	1
Otsuka, K	1
Matsune, S	1
Okubo, K	1
Brinkhaus, B	1
Ortiz, M	1
Witt, CM	1
Roll, S	1
Linde, K	1
Pfab, F	1
Niggemann, B	1
Hummelsberger, J	1
Treszl, A	1
Ring, J	1
Zuberbier, T	1
Wegscheider, K	1
Willich, SN	1
Yamamoto, H	1
Zhang, L	1
Cheng, L	1
Hong, J	1
Vuurman, EF	1
Vuurman, LL	1
Lutgens, I	1
Kremer, B	1
Badawi, AH	1
Tefft, K	1
Fraga, GR	1
Liu, DY	1
Maiello, N	1
Capristo, C	1
Alterio, E	1
Capasso, M	1
Perrone, L	1
Izumi, N	1
Mizuguchi, H	1
Umehara, H	1
Ogino, S	1
Fukui, H	1
Bukstein, DA	1
Lapine, TJ	1
Patel, P	1
Patel, D	1
Mahmoud, F	1
Arifhodzic, N	2
Haines, D	2
Novotney, L	1
Ciebiada, M	1
Ciebiada, MG	1
Kmiecik, T	1
DuBuske, LM	1
Gorski, P	2
Vaidyanathan, S	1
Nair, A	1
Barnes, ML	2
Meldrum, K	1
Lipworth, BJ	7
Badorrek, P	2
Dick, M	2
Schauerte, A	1
Hecker, H	2
Murdoch, R	2
Luettig, B	1
Hohlfeld, JM	2
Krug, N	2
Kuna, P	2
Bachert, C	3
Nowacki, Z	1
van Cauwenberge, P	1
Agache, I	1
Fouquert, L	1
Roger, A	1
Sologuren, A	1
Valiente, R	1
Philip, G	1
van Adelsberg, J	1
Loeys, T	1
Liu, N	1
Wong, P	1
Lai, E	1
Dass, SB	1
Reiss, TF	1
Singh-Franco, D	1
Ghin, HL	1
Robles, GI	1
Borja-Hart, N	1
Perez, A	1
Yuksel, H	1
Sogut, A	1
Yilmaz, H	1
Yilmaz, O	1
Dinc, G	1
Horak, F	4
Phan, H	1
Moeller, ML	1
Nahata, MC	1
Mansfield, LE	1
Hampel, F	3
Haeusler, JM	3
Georges, G	3
Segall, N	1
Gawchik, S	1
Maiti, R	1
Rahman, J	1
Jaida, J	1
Allala, U	1
Palani, A	1
Boev, R	2
Song, D	1
Bedenbaugh, A	1
Pampura, AN	1
Papadopoulos, NG	1
Spičák, V	1
Kurzawa, R	1
Schaumann, F	1
Sousa, AR	1
Ferrer, M	1
Özgür, A	1
Arslanoğlu, S	1
Etıt, D	1
Demıray, U	1
Önal, HK	1
Fang, SY	1
Perng, DW	1
Lee, JY	1
Lin, DY	1
Huangs, CY	1
Romo, CA	1
Joshi, KG	1
Waters, BM	1
Mösges, R	1
König, V	1
Köberlein, J	1
Daley-Yates, P	1
Ambery, C	1
Sweeney, L	1
Watson, J	1
Oliver, A	1
McQuade, B	1
Guilemany, JM	1
García-Piñero, A	1
Alobid, I	1
Centellas, S	1
Mariño, FS	1
Valero, A	1
Bernal-Sprekelsen, M	1
Picado, C	1
Mullol, J	2
Zaĭtseva, OV	1
Mahmoud, FF	1
Al-Awadhi, R	1
Abal, A	1
Azeamouzi, C	1
Al-Sharah, S	1
Tosaki, A	1
Kayasuga, R	1
Sugimoto, Y	1
Watanabe, T	1
Kamei, C	1
Noonan, MJ	2
Raphael, GD	1
Nayak, A	2
Greos, L	1
Olufade, AO	1
Leidy, NK	1
Champan, D	1
Kramer, B	3
Portnoy, JM	2
Simon, SD	1
Ratner, P	2
Mansfield, L	1
Meeves, S	1
Liao, Y	1
Dinakar, C	1
Amit, A	1
Saxena, VS	1
Pratibha, N	1
D'Souza, P	1
Bagchi, M	1
Bagchi, D	1
Stohs, SJ	1
Jackson, CM	1
Kurowski, M	1
Di Lorenzo, G	1
Pacor, ML	1
Pellitteri, ME	1
Morici, G	1
Di Gregoli, A	1
Lo Bianco, C	1
Ditta, V	1
Martinelli, N	1
Candore, G	1
Mansueto, P	1
Rini, GB	1
Corrocher, R	1
Caruso, C	1
Pitsiu, M	1
Hussein, Z	1
Majid, O	1
Aarons, L	1
de Longueville, M	1
Stockis, A	1
Day, JH	5
Briscoe, MP	2
Rafeiro, E	3
Ratz, JD	1
Tosca, MA	4
Milanese, M	2
Schenone, G	1
Ricca, V	5
Magnan, A	1
Cirillo, I	2
Vizzaccaro, A	2
Stübner, P	3
Bloebaum, RM	1
Grant, JA	2
Bousquet, J	4
Canonica, GW	6
Durham, SR	1
Klimek, L	1
Van Cauwenberge, PB	1
Van Hammée, G	1
Kavina, A	2
Corrado, ME	1
Assandri, A	1
Mion, A	1
Riechelmann, H	1
de Blic, J	1
Wahn, U	1
Billard, E	1
Alt, R	1
Pujazon, MC	1
Giovannini, M	1
Braccioni, F	1
Sella, G	1
Contoli, M	1
Perri, G	1
Frati, F	1
Incorvaia, C	1
Martínez-Cócera, C	1
De Molina, M	1
Martí-Guadaño, E	1
Pola, J	1
Conde, J	1
Borja, J	1
Pérez, I	1
Arnaiz, E	1
Izquierdo, I	1
Hyo, S	1
Fujieda, S	1
Kawada, R	1
Kitazawa, S	1
Takenaka, H	1
Corren, J	1
Storms, W	1
Bernstein, J	2
Berger, W	2
Sacks, H	2
Conboy-Ellis, K	1
Passalacqua, G	5
Rajput, A	1
Baerg, K	1
Shedden, A	1
Ward, JH	1
Fardon, TC	1
Hair, PI	1
Scott, LJ	1
Spangler, DL	1
Brunton, S	1
Jorissen, M	1
Bertrand, B	1
Stiels, B	1
Vandenbulcke, K	1
Shah, S	1
Meltzer, EO	3
Nathan, RA	1
Finn, AF	1
LaForce, C	1
Chapman, D	2
de Guia, EC	1
Hewlett, D	1
Lehman, JM	1
Blaiss, MS	1
Moneret-Vautrin, DA	1
de Chillou, C	1
Codreanu, A	1
Korsgren, M	1
Andersson, M	2
Borgå, O	1
Larsson, L	1
Aldén-Raboisson, M	1
Malmqvist, U	1
Greiff, L	1
Young, D	1
Cravo, M	1
Gonçalo, M	1
Figueiredo, A	1
Al Suleimani, YM	1
Dong, Y	1
Walker, MJ	1
Devillier, P	1
Roche, N	1
Faisy, C	1
De Vos, C	2
Mitchev, K	1
Pinelli, ME	2
Derde, MP	1
Buscaglia, S	1
Pesce, G	1
Rihoux, JP	3
Bagnasco, M	2
Hilberg, O	1
Grymer, LF	1
Pedersen, OF	1
Broide, D	1
Tarchalska-Kryńska, B	1
Zawisza, E	1
DuBuske, L	1
Nicodemus, CF	2
Findlay, SR	1
Glovsky, MM	1
Grossman, J	2
Kaiser, H	1
Mitchell, DQ	4
Pearlman, D	1
Selner, J	1
Androsov, VN	1
Belostotskaia, OI	1
Il'ina, NI	1
Naclerio, RM	2
Allegra, L	1
Paupe, J	1
Wieseman, HG	1
Baelde, Y	1
Kaiser, HB	2
Masi, M	1
Candiani, R	1
van de Venne, H	1
Lockey, RF	2
Findley, S	1
Woehler, T	3
Lieberman, P	1
Barnes, CL	1
McKenzie, CA	1
Webster, KD	1
Poinsett-Holmes, K	1
Berkowitz, RB	1
Dockhorn, R	3
Lockey, R	1
Findlay, S	1
Howland, WC	1
Weiler, JM	1
Widlitz, MD	3
Nieman, RB	1
Aaronson, DW	1
Lumry, W	1
Harvey, RP	1
Comer, C	1
Sanders, B	1
Westley, R	1
Marsh, W	1
Shapiro, H	1
Wiener, M	1
Gehanno, P	2
Bremard-Oury, C	1
Zeisser, P	1
Charpin, D	1
Godard, P	1
Garay, RP	1
Baehre, M	1
Herman, D	2
Michel, FB	3
Wang, D	1
Clement, P	1
Smitz, J	1
Cohen, B	1
Frossard, N	4
Lacronique, J	2
Melac, M	4
Benabdesselam, O	2
Braun, JJ	1
Glasser, N	2
Pauli, G	3
Pearlman, DS	1
Lumry, WR	1
Winder, JA	1
Clark, RH	1
Gervais, P	1
Campbell, A	1
Chanal, I	1
Czarlewski, W	2
Tosca, M	1
Riccio, AM	1
Pronzato, C	1
Danzig, M	1
Volkerts, ER	1
Mincarini, M	1
Briscoe, M	2
Donnelly, F	2
Burtin, B	2
Persi, L	1
Demoly, P	1
Harris, AG	1
Tisserand, B	1
Stone, BD	1
Sabbah, A	1
Daele, J	1
Wade, AG	1
Ben-Soussen, P	1
Attali, P	1
Howarth, PH	1
Stern, MA	1
Roi, L	1
Reynolds, R	1
Wilson, A	1
Dempsey, OJ	2
Sims, EJ	4
Coutie, WJ	2
Paterson, MC	1
Salmun, LM	1
Gates, D	1
Scharf, M	1
Greiding, L	1
Ramon, F	1
Heithoff, K	1
Walsh, GM	1
Simons, FE	2
Johnston, L	1
Simons, KJ	2
Wilson, AM	3
Orr, LC	3
Aubier, M	1
Neukirch, C	1
Peiffer, C	1
Bouckaert, A	1
Mouchart, M	1
Kotwani, A	1
Puri, R	1
Gupta, U	1
White, PS	1
Gardiner, Q	1
Wellington, K	1
Jarvis, B	1
Schapowal, A	1
Leynadier, F	1
Mees, K	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Mometasone Furoate Nasal Spray in Italian Children With Seasonal Allergic Rhinitis: a Comprehensive Assessment[NCT05301647]		80 participants (Actual)	Observational	2019-06-20	Completed
Acupuncture for Seasonal Allergic Rhinitis (ACUSAR) - A Randomised Controlled Trial[NCT00610584]		422 participants (Actual)	Interventional	2008-04-30	Completed
Efficacy, Safety and Underlying Mechanisms of Sphenopalatine Ganglion Acupuncture for Perennial Allergic Rhinitis: a Randomized, Double-blind, Placebo Controlled Study[NCT04234451]		40 participants (Anticipated)	Interventional	2021-12-01	Not yet recruiting
The Effects of Sphenopalatine Ganglion Acupuncture in Patients With Seasonal Allergic Rhinitis: A Randomized Trial[NCT03282630]		150 participants (Actual)	Interventional	2016-01-16	Completed
Efficacy, Safety and Underlying Mechanisms of Sphenopalatine Ganglion Acupuncture for Seasonal Allergic Rhinitis: a Randomized, Double-blind, Placebo Controlled Study[NCT04052945]		70 participants (Anticipated)	Interventional	2020-03-25	Recruiting
Prospective Longitudinal Study on the Association Between Treatment of Allergic Rhinitis and Cognitive Ability in Children[NCT03714945]		174 participants (Anticipated)	Observational	2017-12-01	Recruiting
Evaluation of the Beneficial Effects of a Nasal Spray of Resveratrol in Children With Seasonal Allergic Rhinitis[NCT02130440]	Phase 3	100 participants (Actual)	Interventional	2012-11-30	Completed
Double-blind, 3 Parallel Randomized Groups, Therapeutic Confirmatory. Clinical Trial to Compare the Efficacy of Levocetirizine 5 mg and Montelukast 10 mg to Placebo in Reducing SAR Symptoms in Ragweed Sensitive Subjects in an EEC.[NCT00315523]	Phase 3	403 participants	Interventional	2006-07-31	Completed
A Placebo Controlled Trial to Evaluate The Effects of Levocetirizine on Nasal Allergen Challenge And Adenosine Monophosphate Challenge In Patients With Intermittent and Persistent Allergic Rhinitis[NCT00679250]	Phase 4	25 participants (Actual)	Interventional	2005-11-30	Completed
Double-blind, Randomised, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Cetirizine 10 mg for the Treatment of Seasonal Allergic Rhinitis.[NCT00504933]	Phase 3	683 participants (Actual)	Interventional	2005-05-31	Completed
A Multicentre, International, Adaptive, Open-label, Repeated Administration Pharmacokinetic Study of Bilastine in Children From 2 to <12 Years of Age With Allergic Rhinoconjunctivitis or Chronic Urticaria[NCT01081574]	Phase 1/Phase 2	36 participants (Actual)	Interventional	2010-01-31	Completed
A Multicenter, Randomized, Double Blind, Crossover Study Comparing the Effect of MK0524 With Placebo and Concomitant Administration of MK0524 Plus Montelukast in Adult Patients With Chronic Asthma[NCT00783601]	Phase 2	130 participants (Actual)	Interventional	2004-10-31	Completed
[NCT00533208]	Phase 2	766 participants (Actual)	Interventional	2003-07-31	Completed
A Randomized, Double-Blind, 4 Way Cross-over, Placebo Controlled Trial to Evaluate the Onset of Action of Bilastine 20 mg vs. Placebo, Cetirizine 10 mg, and Fexofenadine 120 mg in the Vienna Challenge Chamber[NCT00420082]	Phase 2	75 participants (Actual)	Interventional	2006-10-31	Completed
Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age[NCT04957927]	Phase 4	60 participants (Anticipated)	Interventional	2020-12-12	Recruiting
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine 5 mg Once Daily Given for 2 Weeks in Subjects 18 yr of Age and Older With Seasonal Al[NCT00621959]	Phase 4	596 participants (Actual)	Interventional	2008-03-31	Completed
A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Assess the Efficacy's Reproducibility of a Combination of Pseudoephedrine and Cetirizine on Symptom Scores and Rhinomanometry in Patients With Allergic Rhinitis Following Pollen Exposure in[NCT00474890]		70 participants (Anticipated)	Interventional	2007-06-30	Completed
A Double-blind, Placebo-controlled, Randomized Cross-over Single Dose Escalation Study and a Double-blind, Placebo-controlled, Randomised Parallel Group 7-days Once Daily Repeat Dose Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmaco[NCT00605852]	Phase 1	29 participants (Actual)	Interventional	2007-10-29	Completed
A Randomised, Double-blind, Placebo-controlled, 4-period Incomplete Block Crossover Study of Single Oral Dose GSK835726 (100mg, 50mg, 10mg), Cetirizine (10mg) and Placebo to Evaluate the Efficacy and Safety Using an Environmental Challenge Chamber in Male[NCT00851344]	Phase 2	54 participants (Actual)	Interventional	2008-09-30	Completed
A Double-blind, Placebo-controlled, Randomized Single Dose Escalation Study and a Double-blind, Placebo-controlled, Randomised Parallel Group 14-days Once Daily Repeat Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of an Intranasal H1[NCT00694993]	Phase 1	19 participants (Actual)	Interventional	2007-12-17	Completed
A Randomised, Double-blind, Placebo-controlled 4-period Cross-over Study to Assess the Efficacy and Safety of Repeat Dose Intranasal GSK1004723 (1000µg), Oral GSK835726 (10mg) and Cetirizine (10mg) in the Environmental Challenge Chamber in Subjects With S[NCT00972504]	Phase 2	54 participants (Actual)	Interventional	2009-06-01	Completed
The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis[NCT00119015]	Phase 4	102 participants (Actual)	Interventional	2005-07-31	Terminated (stopped due to Difficulty in recruitment)
Is Levocetirizine Less Sedating Than Cetirizine? A Randomized, Double-blind, Placebo Controlled Trial.[NCT00826943]	Phase 4	30 participants (Actual)	Interventional	2009-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The RQLQ is a validated instrument composed of 28 questions covering 7 dimensions of health. Each question is scored on a scale of 0 to 6 (in which 0 = not troubled and 6 = extremely troubled), and the mean value for each health dimension is calculated. Overall health-related quality of life is expressed as the mean of the seven dimension scores. The overall RQLQ score varies from 0 to 6. (NCT00621959)
Timeframe: Baseline and endpoint, defined as the last available post-baseline observation during the two-week treatment period (in days)

Mean 24-hour Reflective Total 5 Symptoms Score (T5SS)

Intervention	points on a scale (Mean)
Placebo	-1.07
LCTZ	-1.12

Total 5 Symptoms Score (T5SS) is the sum of rhinorrhea, sneezing, nasal congestion, itchy nose and itchy eyes scores. Each individual symptom was scored from 0 (none) to 3 (severe). The total score varies from 0 to 15. (NCT00621959)
Timeframe: Over the total treatment period (14 days)

Weighted Mean Nasal Congestion VAS 1-6 Hours Post Start of Allergen Challenge (2-7 Hours Post-dose) on Day 3

Intervention	points on a scale (Mean)
Placebo	8.96
LCTZ	8.77

On the third dosing day, participants entered the ECC for a duration of 6 hours, 1 hour after receiving their third dose. Time 0 hour was considered as the time that the participant entered the ECC. Nasal congestion was measured on 0-10 centimeter VAS scale (0: no symptoms and 10: the worst possible symptoms) with low score indicates well-being and higher values indicate greater congestion. It was measured at 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340 and 360 minutes. The adjusted mean is provided as least square mean. (NCT00972504)
Timeframe: Day 3 of each treatment period (approximately up to 63 days)

Weighted Mean TNSS (Sneeze, Itch, Rhinorrhoea and Nasal Blockage) 1-6 Hours Post Start of Allergen Challenge (2-7 Hours Post-dose) on Day 3

Intervention	Score on a scale (Least Squares Mean)
Placebo	3.97
GSK1004723 1000 µg Once Daily	4.29
GSK835726 10 mg Once Daily	2.92
Cetirizine 10 mg Once Daily	2.90

On the third dosing day, participants entered the ECC for a duration of 6 hours, 1 hour after receiving their third dose. Time 0 hour was considered as the time that the participant entered the ECC. Nasal blockage, itch, sneeze and rhinorrhoea was scored on a categorical scale from 0 to 3 (0: no symptoms; 1: mild symptoms; 2: moderate symptoms; 3: severe symptoms). The total TNSS ranged from 0-12 point, with low score indicates well-being and higher score indicates more severity. Individual symptoms scores was summed at each time point (0, 20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340 and 360 minutes). The adjusted mean is provided as least square mean. (NCT00972504)
Timeframe: Day 3 of each treatment period (approximately up to 63 days)

Weighted Mean Wet Tissue Weight (as a Surrogate Marker of Nasal Secretion) 1-6 Hours Post Start of Allergen Challenge (2-7 Hours Post-dose) on Day 3

Intervention	Score on a scale (Least Squares Mean)
Placebo	4.9
GSK1004723 1000 µg Once Daily	4.2
GSK835726 10 mg Once Daily	3.6
Cetirizine 10 mg Once Daily	3.5

On the third dosing day, participants entered the ECC for a duration of 6 hours, 1 hour after receiving their third dose. Time 0 hour was considered as the time that the participant entered the ECC. Wet tissue weight assessments was measured as a surrogate marker of nasal secretion at 60, 120, 180, 240, 300 and 360 minutes. The adjusted mean is provided as least square mean. (NCT00972504)
Timeframe: Day 3 of each treatment period (approximately up to 63 days)

Mean Forced Expiratory Volume in 1 Second (FEV1)

Intervention	Grams (Least Squares Mean)
Placebo	6.251
GSK1004723 1000 µg Once Daily	5.210
GSK835726 10 mg Once Daily	4.491
Cetirizine 10 mg Once Daily	3.459

On the third dosing day, participants entered the ECC for a duration of 6 hours, 1 hour after receiving their third dose. Time 0 hour was considered as the time that the participant entered the ECC. FEV1 was measured at pre-challenge, 60, 120, 180, 240, 300 and 360 minutes. (NCT00972504)
Timeframe: Day 3 of each treatment period (approximately up to 63 days)

Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)

Intervention	Liters (Mean)
	FEV1-Pre challenge	FEV1,1 hour	FEV1,2 hour	FEV1,3 hour	FEV1,4 hour	FEV1,5 hour	FEV1,6 hour
Cetirizine 10 mg Once Daily	3.932	3.958	3.925	3.899	3.903	3.858	3.868
GSK1004723 1000 µg Once Daily	3.935	3.959	3.948	3.938	3.913	3.890	3.877
GSK835726 10 mg Once Daily	3.924	3.948	3.936	3.918	3.903	3.890	3.887
Placebo	3.908	3.949	3.910	3.901	3.881	3.858	3.914

An AE was defined as any untoward medical occurrence (MO) in a participant temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP and can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use. The SAE was any untoward MO that, at any dose, results in death, life threatening, persistent or significant disability/incapacity, results in or prolongs inpatient hospitalization, congenital abnormality or birth defect, that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention or is associated with liver injury and impaired liver function defined as: alanine aminotransferase >=3 times upper limit of normal (ULN), and total bilirubin >=2 times ULN or international normalized ratio more than 1.5. (NCT00972504)
Timeframe: approximately up to 63 days

Weighted Mean of the Individual Components of TNSS (Sneeze, Itch, Rhinorrhoea and Nasal Blockage) 1-6 Hours Post Start of Allergen Challenge (2-7 Hours Post-dose) on Day 3

Intervention	Participants (Number)
	Any AE	Any SAE
Cetirizine 10 mg Once Daily	17	0
GSK1004723 1000 µg Once Daily	53	0
GSK835726 10 mg Once Daily	13	0
Placebo	15	0

On the third dosing day, participants entered the ECC for a duration of 6 hours, 1 hour after receiving their third dose. Time 0 hour was considered as the time that the participant entered the ECC. Nasal blockage, itch, sneeze and rhinorrhoea was scored on a categorical scale from 0 to 3 (0: no symptoms; 1: mild symptoms; 2: moderate symptoms; 3: severe symptoms). The total TNSS ranged from 0-12 point, with low score indicates well-being and higher score indicates more severity. Individual symptoms scores was summed to produce the TNSS at each time point (0, 20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340 and 360 minutes). The adjusted mean is provided as least square mean. (NCT00972504)
Timeframe: Day 3 of each treatment period (approximately up to 63 days)

Change From Baseline in Other Symptom Score Over 2 Week Randomized Treatment Period

Intervention	Score on a scale (Least Squares Mean)
	Nasal Blockage	Rhinorrhoea	Nasal Itching	Sneezing
Cetirizine 10 mg Once Daily	1.3	1.0	0.8	0.5
GSK1004723 1000 µg Once Daily	1.7	1.3	0.9	0.4
GSK835726 10 mg Once Daily	1.3	1.1	0.8	0.5
Placebo	1.5	1.5	1.1	0.8

"Patients recorded the severity of other symptoms, including itchy nose/eyes and post-nasal drip, twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The other symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks

Change From Baseline in Runny Nose Symptom Score Over 2 Week Randomized Treatment Period

Intervention	units on a scale (Median)
Fluticasone Propionate + Montelukast	-0.24
Fluticasone Propionate + Placebo	-0.14

"Patients recorded the severity of runny nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The runny nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks

Change From Baseline in Sneezing Symptom Score Over 2 Week Randomized Treatment Period

Intervention	units on a scale (Median)
Fluticasone Propionate + Montelukast	-0.52
Fluticasone Propionate + Placebo	-0.29

"Patients recorded the severity of sneezing twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The sneezing symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks

Change From Baseline in Stuffy Nose Symptom Score Over 2 Week Randomized Treatment Period

Intervention	units on a scale (Median)
Fluticasone Propionate + Montelukast	-0.22
Fluticasone Propionate + Placebo	-0.25

"Patients recorded the severity of stuffy nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The stuffy nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks

Change From Baseline in Total Nasal Symptom Score (TNSS) Over 2 Week Randomized Treatment Period

Intervention	units on a scale (Median)
Fluticasone Propionate + Montelukast	-0.41
Fluticasone Propionate + Placebo	-0.47

"Patients recorded the severity of sneezing, runny nose, stuffy nose, and other symptoms (itchy nose/eyes and post-nasal drip) twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The TNSS was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 24.~The baseline TNSS used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks

Likert Score Rating Global Sedation

Intervention	units on a scale (Median)
Fluticasone Propionate + Montelukast	-1.66
Fluticasone Propionate + Placebo	-2.21

"Likert score range 1 to 9 (no sedation to extreme sedation). Highers scores indicate increased sedation. This was measured on days days 5, 12, 17, 24, 29, and 36 of the study.~This was mean data for all interventions." (NCT00826943)
Timeframe: duration of study (36 days)

Modified Epworth Sleepiness Scale

Intervention	Likert score (Mean)
Placebo	2.80
Levocetirizine	3.07
Cetirizine	3.54

"Epworth Sleepiness Scale ratings (0 to 24); higher scores = increased sedation. This was measured over the 36 days of the study (at the end of each washout period and each intervention period); measured on days 5, 12, 17, 24, 29, and 36.~This was mean data for all interventions." (NCT00826943)
Timeframe: 36 days of the study

Total Four Symptom Scores (Allergy Symptoms)

Intervention	units on a scale (Mean)
Placebo	6.14
Levocetirizine	6.69
Cetirizine	7.48

"Total Four Symptom Scores (TFSS) ranging 0 to 12. Increased scores indicate increased symptoms. This was measured on days 5, 12, 17, 24, 29, and 36 of the study. The mean TFSS for patients receiving placebo, cetirizine, and levocetirizine was then calculated.~This was mean data for all interventions." (NCT00826943)
Timeframe: same as primary outcome measure (obtain on days 5, 12, 17, 24, 29, and 36)

Article	Year
Antiallergic activities of shallot (Allium ascalonicum L.) and its therapeutic effects in allergic rhinitis. Asian Pacific journal of allergy and immunology, 2022, Volume: 40, Issue:4 Topics: Anti-Allergic Agents; Cetirizine; Double-Blind Method; Humans; Plant Extracts; Quercetin; Rhinitis,	2022
Efficacy of Desloratadine and Levocetirizine in Patients with Cedar Pollen-Induced Allergic Rhinitis: A Randomized, Double-Blind Study. International archives of allergy and immunology, 2019, Volume: 180, Issue:4 Topics: Adult; Cedrus; Cetirizine; Cross-Over Studies; Double-Blind Method; Female; Histamine H1 Antagonists	2019
Cetirizine inhibits gender-specific blood cell dynamics upon allergen contact in allergic rhinitis. Clinical immunology (Orlando, Fla.), 2020, Volume: 215 Topics: Adult; Allergens; Cetirizine; Double-Blind Method; Eosinophils; Female; Histamine H1 Antagonists; Hu	2020
Randomized, placebo-controlled study of cetirizine and loratadine in children with seasonal allergic rhinitis. Allergy and asthma proceedings, 2017, May-01, Volume: 38, Issue:3 Topics: Anti-Allergic Agents; Cetirizine; Child; Female; Headache; Humans; Loratadine; Male; Pharyngitis; Rh	2017
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Annals of internal medicine, 2013, Feb-19, Volume: 158, Issue:4 Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E;	2013
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Annals of internal medicine, 2013, Feb-19, Volume: 158, Issue:4 Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E;	2013
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Annals of internal medicine, 2013, Feb-19, Volume: 158, Issue:4 Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E;	2013
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Annals of internal medicine, 2013, Feb-19, Volume: 158, Issue:4 Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E;	2013
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Annals of internal medicine, 2013, Feb-19, Volume: 158, Issue:4 Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E;	2013
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Annals of internal medicine, 2013, Feb-19, Volume: 158, Issue:4 Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E;	2013
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Annals of internal medicine, 2013, Feb-19, Volume: 158, Issue:4 Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E;	2013
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Annals of internal medicine, 2013, Feb-19, Volume: 158, Issue:4 Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E;	2013
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Annals of internal medicine, 2013, Feb-19, Volume: 158, Issue:4 Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E;	2013
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Annals of internal medicine, 2013, Feb-19, Volume: 158, Issue:4 Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E;	2013
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Annals of internal medicine, 2013, Feb-19, Volume: 158, Issue:4 Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E;	2013
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Annals of internal medicine, 2013, Feb-19, Volume: 158, Issue:4 Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E;	2013
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Annals of internal medicine, 2013, Feb-19, Volume: 158, Issue:4 Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E;	2013
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Annals of internal medicine, 2013, Feb-19, Volume: 158, Issue:4 Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E;	2013
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Annals of internal medicine, 2013, Feb-19, Volume: 158, Issue:4 Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E;	2013
Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Annals of internal medicine, 2013, Feb-19, Volume: 158, Issue:4 Topics: Acupuncture Therapy; Betula; Cetirizine; Female; Histamine H1 Antagonists; Humans; Immunoglobulin E;	2013
Randomized double-blind study of prophylactic treatment with an antihistamine for seasonal allergic rhinitis. International archives of allergy and immunology, 2013, Volume: 162, Issue:1 Topics: Cetirizine; Double-Blind Method; Histamine Antagonists; Humans; Rhinitis, Allergic, Seasonal; Treatm	2013
Allergic rhinitis is a risk factor for traffic safety. Allergy, 2014, Volume: 69, Issue:7 Topics: Adult; Androstadienes; Anti-Allergic Agents; Automobile Driving; Cetirizine; Cross-Over Studies; Dou	2014
Resveratrol plus carboxymethyl-β-glucan reduces nasal symptoms in children with pollen-induced allergic rhinitis. Current medical research and opinion, 2014, Volume: 30, Issue:10 Topics: Administration, Intranasal; Allergens; Anti-Allergic Agents; Anti-Inflammatory Agents; Anti-Inflamma	2014
Efficacy comparison of levocetirizine vs montelukast in ragweed sensitized patients. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2008, Volume: 101, Issue:3 Topics: Abdominal Pain; Acetates; Adolescent; Adult; Aged; Ambrosia; Cetirizine; Cyclopropanes; Double-Blind	2008
Levocetirizine modulates lymphocyte activation in patients with allergic rhinitis. Journal of pharmacological sciences, 2008, Volume: 108, Issue:2 Topics: Adult; Anti-Inflammatory Agents; Cetirizine; Eosinophils; Female; Histamine H1 Antagonists, Non-Seda	2008
Quality of life in patients with persistent allergic rhinitis treated with montelukast alone or in combination with levocetirizine or desloratadine. Journal of investigational allergology & clinical immunology, 2008, Volume: 18, Issue:5 Topics: Acetates; Adolescent; Adult; Aged; Cetirizine; Chronic Disease; Cross-Over Studies; Cyclopropanes; D	2008
Effect of levocetirizine on nasal provocation testing with adenosine monophosphate compared with allergen challenge in allergic rhinitis. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2009, Volume: 39, Issue:3 Topics: Adenosine Monophosphate; Adult; Aged; Allergens; Area Under Curve; Cetirizine; Cross-Over Studies; D	2009
A combination of cetirizine and pseudoephedrine has therapeutic benefits when compared to single drug treatment in allergic rhinitis. International journal of clinical pharmacology and therapeutics, 2009, Volume: 47, Issue:2 Topics: Adult; Cetirizine; Cross-Over Studies; Double-Blind Method; Drug Combinations; Drug Synergism; Femal	2009
Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2009, Volume: 39, Issue:9 Topics: Adolescent; Adult; Aged; Benzimidazoles; Cetirizine; Child; Double-Blind Method; Female; Histamine H	2009
Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2009, Volume: 39, Issue:9 Topics: Adolescent; Adult; Aged; Benzimidazoles; Cetirizine; Child; Double-Blind Method; Female; Histamine H	2009
Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2009, Volume: 39, Issue:9 Topics: Adolescent; Adult; Aged; Benzimidazoles; Cetirizine; Child; Double-Blind Method; Female; Histamine H	2009
Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2009, Volume: 39, Issue:9 Topics: Adolescent; Adult; Aged; Benzimidazoles; Cetirizine; Child; Double-Blind Method; Female; Histamine H	2009
Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis. The Journal of allergy and clinical immunology, 2009, Volume: 124, Issue:5 Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Anti-Asthmatic Agents; Asthma; Cetirizine;	2009
Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis. The Journal of allergy and clinical immunology, 2009, Volume: 124, Issue:5 Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Anti-Asthmatic Agents; Asthma; Cetirizine;	2009
Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis. The Journal of allergy and clinical immunology, 2009, Volume: 124, Issue:5 Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Anti-Asthmatic Agents; Asthma; Cetirizine;	2009
Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis. The Journal of allergy and clinical immunology, 2009, Volume: 124, Issue:5 Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Anti-Asthmatic Agents; Asthma; Cetirizine;	2009
The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2010, Volume: 59, Issue:5 Topics: Adolescent; Adult; Allergens; Anti-Allergic Agents; Benzimidazoles; Cetirizine; Cross-Over Studies;	2010
The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2010, Volume: 59, Issue:5 Topics: Adolescent; Adult; Allergens; Anti-Allergic Agents; Benzimidazoles; Cetirizine; Cross-Over Studies;	2010
The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2010, Volume: 59, Issue:5 Topics: Adolescent; Adult; Allergens; Anti-Allergic Agents; Benzimidazoles; Cetirizine; Cross-Over Studies;	2010
The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2010, Volume: 59, Issue:5 Topics: Adolescent; Adult; Allergens; Anti-Allergic Agents; Benzimidazoles; Cetirizine; Cross-Over Studies;	2010
Study of levocetirizine in seasonal allergic rhinitis. Current medical research and opinion, 2010, Volume: 26, Issue:6 Topics: Adolescent; Adult; Aged; Cetirizine; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Seda	2010
Efficacy and safety of levocetirizine in improving symptoms and health-related quality of life in US adults with seasonal allergic rhinitis: a randomized, placebo-controlled study. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2010, Volume: 104, Issue:3 Topics: Adolescent; Adult; Aged; Cetirizine; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Seda	2010
Rupatadine and levocetirizine for seasonal allergic rhinitis: a comparative study of efficacy and safety. Archives of otolaryngology--head & neck surgery, 2010, Volume: 136, Issue:8 Topics: Adolescent; Adult; Cetirizine; Conjunctivitis, Allergic; Cyproheptadine; Eosinophils; Female; Histam	2010
Anti-allergic drug testing in an environmental challenge chamber is suitable both in and out of the relevant pollen season. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2011, Volume: 106, Issue:4 Topics: Adult; Area Under Curve; Atmosphere Exposure Chambers; Cetirizine; Cross-Over Studies; Double-Blind	2011
An open-label, multicentre study of levocetirizine for the treatment of allergic rhinitis and urticaria in Taiwanese patients. The Chinese journal of physiology, 2010, Aug-31, Volume: 53, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cetirizine; Child; Female; Histamine H1 Antagonists, Non	2010
The loss of smell in persistent allergic rhinitis is improved by levocetirizine due to reduction of nasal inflammation but not nasal congestion (the CIRANO study). International archives of allergy and immunology, 2012, Volume: 158, Issue:2 Topics: Adult; Cetirizine; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Infl	2012
The health-related quality of life effects of once-daily cetirizine HCl in patients with seasonal allergic rhinitis: a randomized double-blind, placebo-controlled trial. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2003, Volume: 33, Issue:3 Topics: Adolescent; Adult; Aged; Analysis of Variance; Cetirizine; Double-Blind Method; Female; Humans; Male	2003
Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2003, Volume: 91, Issue:4 Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Cetirizine; Child; Double-Blind Method; Female; Human	2003
Montelukast plus cetirizine in the prophylactic treatment of seasonal allergic rhinitis: influence on clinical symptoms and nasal allergic inflammation. Allergy, 2004, Volume: 59, Issue:3 Topics: Acetates; Adolescent; Adult; Cetirizine; Cyclopropanes; Double-Blind Method; Drug Therapy, Combinati	2004
Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2004, Volume: 34, Issue:2 Topics: Acetates; Administration, Intranasal; Adolescent; Adult; Analysis of Variance; Androstadienes; Blood	2004
Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU). International journal of clinical practice, 2004, Volume: 58, Issue:2 Topics: Adolescent; Adult; Cetirizine; Cohort Studies; Double-Blind Method; Female; Histamine H1 Antagonists	2004
Antihistamines added to an antileukotriene in treating seasonal allergic rhinitis: histamine and leukotriene antagonism. European annals of allergy and clinical immunology, 2004, Volume: 36, Issue:2 Topics: Acetates; Adolescent; Adult; Asthma; Cetirizine; Cyclopropanes; Double-Blind Method; Drug Synergism;	2004
Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2004, Volume: 34, Issue:6 Topics: Adult; Cetirizine; Double-Blind Method; Eosinophils; Female; Histamine H1 Antagonists; Humans; Inter	2004
A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit - the Vienna Challenge Chamber (VCC). Current medical research and opinion, 2004, Volume: 20, Issue:6 Topics: Cetirizine; Cross-Over Studies; Double-Blind Method; Environmental Exposure; Female; Histamine H1 An	2004
Levocetirizine: the allergist's arsenal grows larger. Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:7 Topics: Allergy and Immunology; Cetirizine; Chronic Disease; Clinical Trials, Phase III as Topic; Double-Bli	2004
Cetirizine reduces cytokines and inflammatory cells in children with perennial allergic rhinitis. European annals of allergy and clinical immunology, 2004, Volume: 36, Issue:6 Topics: Adolescent; Animals; Cetirizine; Child; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Eosi	2004
Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. The Journal of allergy and clinical immunology, 2004, Volume: 114, Issue:4 Topics: Adolescent; Adult; Aged; Cetirizine; Conjunctivitis, Allergic; Costs and Cost Analysis; Double-Blind	2004
Clinical study of the therapeutic efficacy and safety of emedastine difumarate versus cetirizine in the treatment of seasonal allergic rhinitis. Arzneimittel-Forschung, 2004, Volume: 54, Issue:10 Topics: Adolescent; Adult; Anti-Allergic Agents; Benzimidazoles; Cetirizine; Cross-Over Studies; Double-Blin	2004
Bacillus clausii effects in children with allergic rhinitis. Allergy, 2005, Volume: 60, Issue:5 Topics: Adolescent; Bacillus; Cetirizine; Double-Blind Method; Eosinophils; Female; Histamine H1 Antagonists	2005
Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2005, Volume: 16, Issue:3 Topics: Adolescent; Cetirizine; Child; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Sedating;	2005
Comparison of allergen immunotherapy and drug treatment in seasonal rhinoconjunctivitis: a 3-years study. European annals of allergy and clinical immunology, 2005, Volume: 37, Issue:2 Topics: Administration, Intranasal; Adolescent; Adult; Allergens; Anti-Allergic Agents; Anti-Inflammatory Ag	2005
Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel study. Journal of investigational allergology & clinical immunology, 2005, Volume: 15, Issue:1 Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Cetirizine; Child; Cyproheptadine; Double-Blind Metho	2005
The efficacy of short-term administration of 3 antihistamines vs placebo under natural exposure to Japanese cedar pollen. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2005, Volume: 94, Issue:4 Topics: Adult; Cetirizine; Cryptomeria; Double-Blind Method; Drug Administration Schedule; Female; Histamine	2005
Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis. Clinical therapeutics, 2005, Volume: 27, Issue:5 Topics: Administration, Intranasal; Adolescent; Adult; Aged; Cetirizine; Child; Double-Blind Method; Female;	2005
Effects of levocetirizine as add-on therapy to fluticasone in seasonal allergic rhinitis. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2006, Volume: 36, Issue:5 Topics: Administration, Intranasal; Adolescent; Adult; Aged; Androstadienes; Anti-Allergic Agents; Cetirizin	2006
Levocetirizine as treatment for symptoms of seasonal allergic rhinitis. B-ENT, 2006, Volume: 2, Issue:2 Topics: Adolescent; Adult; Aged; Cetirizine; Histamine H1 Antagonists; Histamine H1 Antagonists, Non-Sedatin	2006
Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2006, Volume: 97, Issue:3 Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Aged; Anti-Allergic Agents; Ant	2006
Comparison of cetirizine-pseudoephedrine and placebo in patients with seasonal allergic rhinitis and concomitant mild-to-moderate asthma: randomized, double-blind study. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2006, Volume: 97, Issue:3 Topics: Adrenergic Agents; Adult; Anti-Asthmatic Agents; Asthma; Cetirizine; Drug Combinations; Ephedrine; F	2006
Clinical efficacy and pharmacokinetic profiles of intranasal and oral cetirizine in a repeated allergen challenge model of allergic rhinitis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2007, Volume: 98, Issue:4 Topics: Administration, Oral; Adult; Allergens; Anti-Allergic Agents; Cetirizine; Dose-Response Relationship	2007
Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. The Journal of allergy and clinical immunology, 1995, Volume: 95, Issue:2 Topics: Adolescent; Adult; Allergens; Cetirizine; Conjunctiva; Conjunctivitis, Allergic; Double-Blind Method	1995
[Test for efficacy of cetirizine and loratadine as a treatment for seasonal allergic rhinitis in a 6 week cross-over comparative study]. Pneumonologia i alergologia polska, 1994, Volume: 62, Issue:11-12 Topics: Adolescent; Adult; Cetirizine; Conjunctivitis; Cross-Over Studies; Female; Humans; Loratadine; Male;	1994
Dose-ranging comparative evaluation of cetirizine in patients with seasonal allergic rhinitis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1995, Volume: 74, Issue:4 Topics: Adolescent; Adult; Aged; Cetirizine; Child; Drug Evaluation; Female; Histamine H1 Antagonists; Human	1995
Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. The Journal of allergy and clinical immunology, 1995, Volume: 95, Issue:5 Pt 1 Topics: Adolescent; Adult; Albuterol; Asthma; Cetirizine; Double-Blind Method; Ephedrine; Humans; Male; Plac	1995
[The efficacy of the Zirtek (cetirizine) preparation in chronic recurrent urticaria and seasonal allergic rhinitis]. Terapevticheskii arkhiv, 1994, Volume: 66, Issue:11 Topics: Adolescent; Adult; Cetirizine; Chronic Disease; Drug Therapy, Combination; Female; Humans; Male; Mid	1994
The effect of antihistamines on the immediate allergic response: a comparative review. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 1993, Volume: 108, Issue:6 Topics: Capillary Permeability; Cetirizine; Cyproheptadine; Diphenhydramine; Double-Blind Method; Histamine	1993
Cetirizine for seasonal allergic rhinitis in children aged 2-6 years. A double-blind comparison with placebo. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 1993, Volume: 4, Issue:3 Topics: Cetirizine; Child; Child, Preschool; Double-Blind Method; Female; Humans; Male; Rhinitis, Allergic,	1993
A placebo-controlled trial of cetirizine in seasonal allergic rhino-conjunctivitis in children aged 6 to 12 years. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 1993, Volume: 4, Issue:4 Suppl Topics: Cetirizine; Child; Conjunctivitis, Allergic; Double-Blind Method; Female; Humans; Male; Rhinitis, Al	1993
Effects of cetirizine versus terfenadine in seasonal allergic rhinitis. Annals of allergy, 1993, Volume: 70, Issue:4 Topics: Adult; Cetirizine; Female; Humans; Male; Middle Aged; Patient Satisfaction; Rhinitis, Allergic, Seas	1993
Comparison of efficacy, safety, and skin test inhibition of cetirizine and astemizole. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1996, Volume: 76, Issue:4 Topics: Adolescent; Adult; Aged; Analysis of Variance; Anti-Allergic Agents; Astemizole; Cetirizine; Child;	1996
Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. The Journal of allergy and clinical immunology, 1996, Volume: 97, Issue:2 Topics: Adolescent; Adult; Cetirizine; Child; Double-Blind Method; Female; Humans; Loratadine; Male; Middle	1996
Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1996, Volume: 76, Issue:5 Topics: Adolescent; Adult; Asthma; Cetirizine; Female; Humans; Male; Medical Records; Middle Aged; Patient S	1996
Comparative study of cetirizine and terfenadine versus placebo in the symptomatic management of seasonal allergic rhinitis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1996, Volume: 76, Issue:5 Topics: Adolescent; Adult; Aged; Cetirizine; Child; Double-Blind Method; Ephedrine; Female; Humans; Male; Mi	1996
Model for outcomes assessment of antihistamine use for seasonal allergic rhinitis. The Journal of allergy and clinical immunology, 1996, Volume: 97, Issue:6 Topics: Adolescent; Adult; Cetirizine; Chlorpheniramine; Decision Making; Female; Formularies as Topic; Hist	1996
Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1996, Volume: 76, Issue:6 Topics: Adult; Butyrophenones; Cetirizine; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; Ma	1996
A multicenter clinical study of the efficacy and tolerability of azelastine nasal spray in the treatment of seasonal allergic rhinitis: a comparison with oral cetirizine. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 1995, Volume: 252, Issue:8 Topics: Administration, Inhalation; Adolescent; Adult; Cetirizine; Child; Histamine H1 Antagonists; Humans;	1995
Comparison of the efficacy of ebastine 10mg and 20mg once daily with that of cetirizine 10mg once daily in adults with seasonal allergic rhinitis. A multicentre double-blind study. Drugs, 1996, Volume: 52 Suppl 1 Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Butyrophenones; Cetirizine; Double-Blind Method; Fema	1996
Onset of action in the nasal antihistaminic effect of cetirizine and loratadine in patients with allergic rhinitis. Allergy, 1997, Volume: 52, Issue:2 Topics: Adult; Airway Resistance; Animals; Cetirizine; Cross-Over Studies; Double-Blind Method; Female; Hist	1997
Once-daily cetirizine effective in the treatment of seasonal allergic rhinitis in children aged 6 to 11 years: a randomized, double-blind, placebo-controlled study. Clinical pediatrics, 1997, Volume: 36, Issue:4 Topics: Cetirizine; Child; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; Male; Rhinitis, Al	1997
Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1997, Volume: 79, Issue:2 Topics: Adolescent; Adult; Anti-Allergic Agents; Astemizole; Cetirizine; Double-Blind Method; Environmental	1997
Reduction of soluble ICAM-1 levels in nasal secretion by H1-blockers in seasonal allergic rhinitis. Allergy, 1997, Volume: 52, Issue:10 Topics: Adult; Albumins; Cetirizine; Double-Blind Method; Epithelial Cells; Histamine H1 Antagonists; Humans	1997
Cetirizine treatment of rhinitis in children with pollen allergy: evidence of its antiallergic activity. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 1997, Volume: 27, Issue:10 Topics: Adolescent; Anti-Allergic Agents; Blood Proteins; Cetirizine; Child; Double-Blind Method; Eosinophil	1997
Loratadine treatment of rhinitis due to pollen allergy reduces epithelial ICAM-1 expression. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 1997, Volume: 27, Issue:10 Topics: Adolescent; Adult; Blood Proteins; Cetirizine; Eosinophil Granule Proteins; Eosinophil Peroxidase; E	1997
Continuous versus on demand treatment with cetirizine for allergic rhinitis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1997, Volume: 79, Issue:6 Topics: Adult; Anti-Allergic Agents; Cetirizine; Double-Blind Method; Female; Humans; Male; Middle Aged; Rhi	1997
Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. The Journal of allergy and clinical immunology, 1998, Volume: 101, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allergens; Anti-Allergic Agents; Cetirizine; Double-Blin	1998
Nasal effect of cetirizine and loratadine at 24 hours in patients with allergic rhinitis. American journal of therapeutics, 1998, Volume: 5, Issue:5 Topics: Adult; Cetirizine; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female	1998
Comparison between nasal provocation tests and skin tests in patients treated with loratadine and cetirizine. The Journal of allergy and clinical immunology, 1999, Volume: 103, Issue:4 Topics: Adult; Allergens; Anti-Allergic Agents; Cetirizine; Cross-Over Studies; Double-Blind Method; Female;	1999
Comparison of the efficacy, safety, and onset of action of mizolastine, cetirizine, and placebo in the management of seasonal allergic rhinoconjunctivitis. MIZOCET Study Group. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1999, Volume: 83, Issue:4 Topics: Adolescent; Adult; Anti-Allergic Agents; Benzimidazoles; Cetirizine; Conjunctivitis, Allergic; Doubl	1999
Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. The Journal of allergy and clinical immunology, 1999, Volume: 104, Issue:5 Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Cetirizine; Child; Double-Blind Method; Drug Administ	1999
Evaluation of treatment response in patients with seasonal allergic rhinitis using domiciliary nasal peak inspiratory flow. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2000, Volume: 30, Issue:6 Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Cetirizine; Cyclopropanes; Drug Therapy, Co	2000
Loratadine versus cetirizine: assessment of somnolence and motivation during the workday. Clinical therapeutics, 2000, Volume: 22, Issue:5 Topics: Adult; Anti-Allergic Agents; Cetirizine; Disorders of Excessive Somnolence; Double-Blind Method; Eff	2000
Clinical pharmacology of the H1-receptor antagonists cetirizine and loratadine in children. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2000, Volume: 11, Issue:2 Topics: Anti-Allergic Agents; Cetirizine; Child; Cross-Over Studies; Double-Blind Method; Histamine H1 Antag	2000
Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma. American journal of respiratory and critical care medicine, 2000, Volume: 162, Issue:4 Pt 1 Topics: Acetates; Administration, Inhalation; Administration, Oral; Anti-Asthmatic Agents; Asthma; Bronchial	2000
Effect of cetirizine on bronchial hyperresponsiveness in patients with seasonal allergic rhinitis and asthma. Allergy, 2001, Volume: 56, Issue:1 Topics: Adult; Anti-Allergic Agents; Asthma; Bronchial Hyperreactivity; Bronchoconstrictor Agents; Cetirizin	2001
Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2001, Volume: 31, Issue:1 Topics: Acetates; Administration, Intranasal; Anti-Inflammatory Agents; Cetirizine; Cross-Over Studies; Cycl	2001
Efficacy of nimesulide alone and in combination with cetirizine in acute allergic rhinitis. The Journal of the Association of Physicians of India, 2001, Volume: 49 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Cetirizine; Double-Blind Method; Drug Th	2001
Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. International archives of allergy and immunology, 2001, Volume: 125, Issue:1 Topics: Adult; Anti-Allergic Agents; Bronchial Provocation Tests; Cetirizine; Cross-Over Studies; Double-Bli	2001
Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2001, Volume: 87, Issue:4 Topics: Acetates; Administration, Inhalation; Administration, Intranasal; Adult; Airway Resistance; Anti-All	2001
Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2001, Volume: 87, Issue:6 Topics: Adolescent; Adult; Cetirizine; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; Lorata	2001
Randomised controlled trial of butterbur and cetirizine for treating seasonal allergic rhinitis. BMJ (Clinical research ed.), 2002, Jan-19, Volume: 324, Issue:7330 Topics: Adult; Asteraceae; Cetirizine; Fatigue; Female; Histamine H1 Antagonists; Humans; Male; Middle Aged;	2002
Efficacy and safety of levocetirizine in seasonal allergic rhinitis. Acta oto-rhino-laryngologica Belgica, 2001, Volume: 55, Issue:4 Topics: Adult; Cetirizine; Double-Blind Method; Drug Administration Schedule; Female; Histamine H1 Antagonis	2001
[Cetirizine for treating allergic seasonal rhinitis]. Pneumonologia i alergologia polska, 1992, Volume: 60, Issue:11-12 Topics: Adolescent; Adult; Bronchial Provocation Tests; Cetirizine; Double-Blind Method; Female; Humans; Mal	1992
Inhibition of histamine-induced nasal obstruction by cetirizine in allergic rhinitis. British journal of clinical pharmacology, 1992, Volume: 33, Issue:4 Topics: Adult; Airway Resistance; Cetirizine; Female; Histamine; Histamine H1 Antagonists; Humans; Hydroxyzi	1992
[Clinical effectiveness and tolerance of loratadine versus cetirizine in the treatment of seasonal allergic rhinitis]. Allergie et immunologie, 1992, Volume: 24, Issue:7 Topics: Adult; Cetirizine; Double-Blind Method; Drug Tolerance; Female; Humans; Loratadine; Male; Rhinitis,	1992
Double-blind comparison of cetirizine and placebo in the treatment of seasonal rhinitis. Annals of allergy, 1991, Volume: 66, Issue:3 Topics: Adult; Cetirizine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Histamine H1 Antag	1991
Multicenter, crossover study of the efficacy and tolerability of terfenadine, 120 mg, versus cetirizine, 10 mg, in perennial allergic rhinitis. Annals of allergy, 1991, Volume: 67, Issue:4 Topics: Adult; Cetirizine; Dose-Response Relationship, Drug; Female; Histamine H1 Antagonists; Humans; Hydro	1991
Multicentre, double-blind comparison of terfenadine and cetirizine in patients with seasonal allergic rhinitis. The British journal of clinical practice, 1990, Volume: 44, Issue:3 Topics: Adult; Benzhydryl Compounds; Cetirizine; Double-Blind Method; Histamine H1 Antagonists; Humans; Hydr	1990
Effect of cetirizine in a conjunctival provocation test with allergens. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 1990, Volume: 20, Issue:2 Topics: Adolescent; Adult; Allergens; Cetirizine; Clinical Trials as Topic; Conjunctivitis, Allergic; Double	1990
Efficacy of cetirizine in the treatment of seasonal allergic rhinoconjunctivitis. Annals of allergy, 1990, Volume: 65, Issue:2 Topics: Adult; Cetirizine; Clinical Trials as Topic; Conjunctivitis, Allergic; Double-Blind Method; Histamin	1990
Allergen-induced increase in nonspecific nasal reactivity is blocked by antihistamines without a clear-cut relationship to eosinophil influx. The Journal of allergy and clinical immunology, 1990, Volume: 86, Issue:4 Pt 1 Topics: Allergens; Benzhydryl Compounds; Cetirizine; Double-Blind Method; Eosinophils; Histamine H1 Antagoni	1990
The effects of antihistamines beyond H1 antagonism in allergic inflammation. The Journal of allergy and clinical immunology, 1990, Volume: 86, Issue:6 Pt 2 Topics: Benzhydryl Compounds; Cetirizine; Cyproheptadine; Dermatitis, Atopic; Histamine H1 Antagonists; Hist	1990
The effect of cetirizine on early allergic response. The Laryngoscope, 1989, Volume: 99, Issue:6 Pt 1 Topics: Albumins; Antigens; Cetirizine; Clinical Trials as Topic; Double-Blind Method; Histamine; Histamine	1989
Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. The Journal of allergy and clinical immunology, 1989, Volume: 84, Issue:4 Pt 1 Topics: Cetirizine; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blind Method; Histamin	1989
[Importance of Zyrtec in the treatment of chronic urticaria and allergic rhinopathies apropos of 1168 cases seen by hospital practitioners]. Allergie et immunologie, 1989, Volume: 21, Issue:8 Topics: Adolescent; Adult; Cetirizine; Chronic Disease; Female; Histamine H1 Antagonists; Humans; Hydroxyzin	1989
Inhibitory effect of cetirizine 2HCl on eosinophil migration in vivo. Clinical allergy, 1987, Volume: 17, Issue:4 Topics: Adult; Cell Movement; Cetirizine; Eosinophils; Female; Histamine; Histamine H1 Antagonists; Humans;	1987

Article	Year
[Modern H1 antihistamines in the treatment of patients with allergic rhinitis and comorbid acute respiratory infections]. Vestnik otorinolaringologii, 2022, Volume: 87, Issue:3 Topics: Adult; Cetirizine; Female; Histamine Antagonists; Histamine H1 Antagonists; Humans; Inflammation; Ma	2022
Cetirizine modifies quality of life and symptoms in children with seasonal allergic rhinitis: a pilot study. Acta bio-medica : Atenei Parmensis, 2020, 06-17, Volume: 92, Issue:1 Topics: Cetirizine; Child; Female; Humans; Male; Pilot Projects; Quality of Life; Rhinitis, Allergic, Season	2020
Environmental exposure unit simulates natural seasonal birch pollen exposures while maximizing change in allergic symptoms. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2021, Volume: 127, Issue:4 Topics: Adult; Allergens; Anti-Allergic Agents; Betula; Cetirizine; Environmental Exposure; Female; Humans;	2021
Nasal Symptoms Reduction and Decreased Neutrophilia in Japanese Cedar Pollinosis With Prophylactic Treatment With a Combination of Montelukast, Fexofenadine, and Fluticasone Nasal Spray. American journal of rhinology & allergy, 2019, Volume: 33, Issue:4 Topics: Acetates; Adult; Anti-Allergic Agents; Cetirizine; Cryptomeria; Cyclopropanes; Drug Therapy, Combina	2019
Summaries for patients. The effects of acupuncture on seasonal allergic rhinitis. Annals of internal medicine, 2013, Feb-19, Volume: 158, Issue:4 Topics: Acupuncture Therapy; Cetirizine; Female; Histamine H1 Antagonists; Humans; Male; Quality of Life; Rh	2013
Cetirizine-induced acute generalized exanthematous pustulosis: a serious reaction to a commonly used drug. Dermatology online journal, 2014, May-16, Volume: 20, Issue:5 Topics: Acute Generalized Exanthematous Pustulosis; Anti-Allergic Agents; Cetirizine; Child; Female; Histami	2014
Analysis of disease-dependent sedative profiles of H(1)-antihistamines by large-scale surveillance using the visual analog scale. Methods and findings in experimental and clinical pharmacology, 2008, Volume: 30, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asthma; Butyrophenones; Cetirizine; Child; Chlorpheniram	2008
Sleep actigraphy evidence of improved sleep after treatment of allergic rhinitis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2009, Volume: 103, Issue:4 Topics: Actigraphy; Adolescent; Androstadienes; Anti-Allergic Agents; Cetirizine; Child; Female; Fluticasone	2009
Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast. Drugs, 2009, Volume: 69, Issue:18 Topics: Acetates; Administration, Oral; Adult; Anti-Allergic Agents; Anti-Asthmatic Agents; Astemizole; Ceti	2009
Ahh-choo! How to sneeze at allergies. Consumer reports, 2010, Volume: 75, Issue:5 Topics: Adrenal Cortex Hormones; Cetirizine; Diphenhydramine; Health Behavior; Health Care Surveys; Histamin	2010
Evidence for clinical safety, efficacy, and parent and physician perceptions of levocetirizine for the treatment of children with allergic disease. International archives of allergy and immunology, 2011, Volume: 155, Issue:4 Topics: Adult; Anti-Allergic Agents; Attitude of Health Personnel; Cetirizine; Child; Child, Preschool; Chro	2011
Comparison of nasal cytology and symptom scores in patients with seasonal allergic rhinitis, before and after treatment. The Journal of laryngology and otology, 2011, Volume: 125, Issue:10 Topics: Administration, Intranasal; Adult; Aged; Anti-Allergic Agents; Cetirizine; Drug Therapy, Combination	2011
Involuntary movements associated with cetirizine use. The American journal of psychiatry, 2011, Volume: 168, Issue:8 Topics: Anti-Allergic Agents; Cetirizine; Dysarthria; Dyskinesia, Drug-Induced; Female; Humans; Rhinitis, Al	2011
[Off-season manifestations of pollen hypersensitization]. Vestnik otorinolaringologii, 2011, Issue:6 Topics: Adult; Cetirizine; Conjunctivitis, Allergic; Desensitization, Immunologic; Female; Histamine H1 Anta	2011
In vitro suppression of lymphocyte activation in patients with seasonal allergic rhinitis and pollen-related asthma by cetirizine or azelastine in combination with ginkgolide B or astaxanthin. Acta physiologica Hungarica, 2012, Volume: 99, Issue:2 Topics: Adult; Anti-Allergic Agents; Antioxidants; Asthma; Biomarkers; Case-Control Studies; Cells, Cultured	2012
Participation of chemical mediators other than histamine in nasal allergy signs: a study using mice lacking histamine H(1) receptors. European journal of pharmacology, 2002, Aug-09, Volume: 449, Issue:3 Topics: Animals; Anti-Allergic Agents; Antigens; Behavior, Animal; Carbazoles; Cetirizine; Dose-Response Rel	2002
[In seasonal and perennial rhinitis. Superiority to standard H1 blockers]. MMW Fortschritte der Medizin, 2003, May-29, Volume: 145, Issue:22 Topics: Anti-Allergic Agents; Butyrophenones; Cetirizine; Double-Blind Method; Histamine H1 Antagonists; His	2003
[Antihistaminics. Side effects also after raising dosage at the placebo level]. MMW Fortschritte der Medizin, 2003, May-29, Volume: 145, Issue:22 Topics: Anti-Allergic Agents; Benzimidazoles; Butyrophenones; Cetirizine; Double-Blind Method; Histamine H1	2003
Is 3-mm less drowsiness important? Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2003, Volume: 91, Issue:4 Topics: Anti-Allergic Agents; Automobile Driving; Cetirizine; Humans; Rhinitis, Allergic, Seasonal; Severity	2003
Levocetirizine: new preparation. Me-too: simply the active enantiomer of cetirizine. Prescrire international, 2003, Volume: 12, Issue:67 Topics: Anti-Allergic Agents; Cetirizine; Clinical Trials as Topic; Histamine H1 Antagonists; Humans; Pipera	2003
Mast cell stabilization, lipoxygenase inhibition, hyaluronidase inhibition, antihistaminic and antispasmodic activities of Aller-7, a novel botanical formulation for allergic rhinitis. Drugs under experimental and clinical research, 2003, Volume: 29, Issue:3 Topics: Animals; Barium Compounds; Carbachol; Cetirizine; Chlorides; Dose-Response Relationship, Drug; Drug	2003
Combined mediator antagonism for allergic rhinitis. Allergy, 2004, Volume: 59, Issue:3 Topics: Acetates; Cetirizine; Cyclopropanes; Drug Therapy, Combination; Histamine H1 Antagonists, Non-Sedati	2004
Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 years. British journal of clinical pharmacology, 2004, Volume: 57, Issue:4 Topics: Cetirizine; Child; Child, Preschool; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Seda	2004
[Respiratory allergies in the child and the adult]. La Revue du praticien, 2004, Jan-31, Volume: 54, Issue:2 Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Age Factors; Aged; Allergens; Anti-Allergic Ag	2004
Cetirizine-induced dystonic movements. Neurology, 2006, Jan-10, Volume: 66, Issue:1 Topics: Cetirizine; Child, Preschool; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonic Disorder	2006
[Patient report: allergic rhinitis]. Krankenpflege Journal, 2005, Volume: 43, Issue:7-10 Topics: Absenteeism; Cetirizine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Histamine H1 An	2005
Long QT syndrome in a patient with allergic rhinoconjunctivitis and auto-immune diabetes: focus on the choice of anti-H1 drugs. European annals of allergy and clinical immunology, 2006, Volume: 38, Issue:10 Topics: Adolescent; Adrenergic beta-Antagonists; Anti-Asthmatic Agents; Butyrophenones; Cetirizine; Conjunct	2006
New hay fever, hives treatment approved. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2007, Jul-01, Volume: 64, Issue:13 Topics: Cetirizine; Chronic Disease; Clinical Trials as Topic; Histamine H1 Antagonists, Non-Sedating; Human	2007
Fixed drug eruption to cetirizine with positive lesional patch tests to the three piperazine derivatives. International journal of dermatology, 2007, Volume: 46, Issue:7 Topics: Cetirizine; Cross Reactions; Drug Eruptions; Female; Histamine H1 Antagonists, Non-Sedating; Humans;	2007
Differential responses to various classes of drugs in a model of allergic rhinitis in guinea pigs. Pulmonary pharmacology & therapeutics, 2008, Volume: 21, Issue:2 Topics: Acetates; Acute Disease; Animals; Cetirizine; Cyclopropanes; Dexamethasone; Disease Models, Animal;	2008
Levocetirizine (Xyzal) for allergic rhinitis and urticaria. The Medical letter on drugs and therapeutics, 2007, Dec-03, Volume: 49, Issue:1275 Topics: Cetirizine; Histamine H1 Antagonists; Humans; Piperazines; Rhinitis, Allergic, Perennial; Rhinitis,	2007
Non-interventional study comparing treatment satisfaction in patients treated with antihistamines. Clinical drug investigation, 2008, Volume: 28, Issue:4 Topics: Activities of Daily Living; Administration, Oral; Adult; Aged; Aged, 80 and over; Cetirizine; Child;	2008
Nasal histamine challenge in nonallergic and allergic subjects evaluated by acoustic rhinometry. Allergy, 1995, Volume: 50, Issue:2 Topics: Acoustics; Adolescent; Adult; Cetirizine; Female; Histamine; Humans; Male; Nasal Cavity; Nasal Provo	1995
Cetirizine in patients with seasonal rhinitis and concomitant asthma. The Journal of allergy and clinical immunology, 1996, Volume: 97, Issue:2 Topics: Asthma; Cetirizine; Humans; Rhinitis, Allergic, Seasonal	1996
Effect of H1 and H2 antagonists on nasal symptoms and mediator release in atopic patients after nasal allergen challenge during the pollen season. Acta oto-laryngologica, 1996, Volume: 116, Issue:1 Topics: Adult; Airway Resistance; Cetirizine; Eosinophils; Female; Histamine H1 Antagonists; Histamine H2 An	1996
Comparison of ebastine with cetirizine. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1997, Volume: 79, Issue:5 Topics: Adult; Butyrophenones; Cetirizine; Histamine H1 Antagonists; Humans; Piperidines; Rhinitis, Allergic	1997
The clinical efficacy of H1 antagonists in urticaria and rhinitis. The Journal of allergy and clinical immunology, 1998, Volume: 102, Issue:2 Topics: Anti-Allergic Agents; Cetirizine; Histamine H1 Antagonists; Humans; Loratadine; Mathematical Computi	1998
Same drug, different outcomes in the environmental exposure unit. The Journal of allergy and clinical immunology, 1999, Volume: 103, Issue:4 Topics: Anti-Allergic Agents; Cetirizine; Controlled Clinical Trials as Topic; Histamine H1 Antagonists; Hum	1999
Fexofenadine: new preparation. Terfenadine, without cardiotoxicity. Prescrire international, 1999, Volume: 8, Issue:39 Topics: Cetirizine; Chronic Disease; Clinical Trials as Topic; Drug Evaluation; Histamine Antagonists; Human	1999
Sure outcomes of random events: a model for clinical trials. Statistics in medicine, 2001, Feb-28, Volume: 20, Issue:4 Topics: Cetirizine; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Histamine H1 Antag	2001
Newer antihistamines. The Medical letter on drugs and therapeutics, 2001, Apr-30, Volume: 43, Issue:1103 Topics: Administration, Oral; Anti-Allergic Agents; Cetirizine; Chlorpheniramine; Conscious Sedation; Diphen	2001
[Already allergic to pollen in early childhood. Can future asthma still be prevented?]. MMW Fortschritte der Medizin, 2002, Mar-07, Volume: 144, Issue:10 Topics: Asthma; Cetirizine; Child; Child, Preschool; Histamine H1 Antagonists; Humans; Infant; Pollen; Rando	2002
Treating seasonal allergic rhinitis. Well designed experiments should have been used. BMJ (Clinical research ed.), 2002, May-25, Volume: 324, Issue:7348 Topics: Asteraceae; Cetirizine; Histamine H1 Antagonists; Humans; Phytotherapy; Plant Extracts; Research Des	2002
Treating seasonal allergic rhinitis. Trial does not show that there is no difference between butterbur and cetirizine. BMJ (Clinical research ed.), 2002, May-25, Volume: 324, Issue:7348 Topics: Asteraceae; Cetirizine; Histamine H1 Antagonists; Humans; Phytotherapy; Plant Extracts; Research Des	2002
[Cetirizine in allergic symptoms. General practice relevance and a profile of effects. Resume of current studies]. Fortschritte der Medizin. Supplement : die Kongressinformation fur die Praxis, 1990, Volume: 89 Topics: Asthma; Cetirizine; Eosinophils; Histamine H1 Antagonists; Humans; Hydroxyzine; Rhinitis, Allergic,	1990
Clinical pharmacodynamics of antihistamines. Annals of allergy, 1987, Volume: 59, Issue:6 Pt 2 Topics: Animals; Asthma; Brain; Bronchial Provocation Tests; Cetirizine; Drug Evaluation; Electroencephalogr	1987
A primate model for the evaluation of antihistamines. Annals of allergy, 1987, Volume: 59, Issue:6 Pt 2 Topics: Administration, Oral; Airway Resistance; Animals; Bronchial Provocation Tests; Cetirizine; Chlorphen	1987

cetirizine and Hay Fever